Last Patient enrolled recovers in 10 days, great news
Final patient was enrolled on Nov 30, two weeks of treatment and 2 weeks of follow-up, this means that the patient was released from the hospital on Dec 10th, which is 4 to 5 days sooner than the average. The drug is working, at least the last patient. ( recovered 4 to 5 days faster than the average.)
VANCOUVER, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.